Torsdag 26 December | 23:09:58 Europe / Stockholm

Kalender

Tid*
2025-11-06 07:00 Kvartalsrapport 2025-Q3
2025-08-14 07:00 Kvartalsrapport 2025-Q2
2025-05-08 07:00 Kvartalsrapport 2025-Q1
2025-02-20 18:00 Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-16 - Kvartalsrapport 2024-Q1
2024-03-21 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2024-03-20 - Årsstämma
2024-02-27 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-11 - Kvartalsrapport 2023-Q1
2023-03-30 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2023-03-29 - Årsstämma
2023-03-02 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-11 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-05-09 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2022-04-06 - Årsstämma
2022-03-10 - Bokslutskommuniké 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-08-12 - Kvartalsrapport 2021-Q2
2021-05-12 - Kvartalsrapport 2021-Q1
2021-04-16 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2021-04-15 - Årsstämma
2021-03-11 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-13 - Kvartalsrapport 2020-Q2
2020-05-14 - Kvartalsrapport 2020-Q1
2020-04-03 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2020-04-02 - Årsstämma
2020-03-12 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-15 - Kvartalsrapport 2019-Q2
2019-05-16 - Kvartalsrapport 2019-Q1
2019-04-05 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2019-04-04 - Årsstämma
2019-03-07 - Bokslutskommuniké 2018
2018-11-15 - Kvartalsrapport 2018-Q3
2018-08-16 - Kvartalsrapport 2018-Q2
2018-05-16 - Kvartalsrapport 2018-Q1
2018-04-20 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2018-04-19 - Årsstämma
2018-03-07 - Bokslutskommuniké 2017
2017-11-08 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-05-17 - Kvartalsrapport 2017-Q1
2017-04-06 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2017-04-05 - Årsstämma
2017-03-15 - Bokslutskommuniké 2016
2016-11-09 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-18 - Kvartalsrapport 2016-Q1
2016-04-20 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2016-04-19 - Årsstämma
2016-03-16 - Bokslutskommuniké 2015
2015-11-05 - Kvartalsrapport 2015-Q3
2015-08-28 - Kvartalsrapport 2015-Q2
2015-05-22 - Kvartalsrapport 2015-Q1
2015-04-22 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2015-04-21 - Årsstämma
2015-03-12 - Bokslutskommuniké 2014
2014-11-07 - Kvartalsrapport 2014-Q3
2014-08-21 - Kvartalsrapport 2014-Q2
2014-05-06 - Kapitalmarknadsdag 2014
2014-04-29 - Årsstämma
2014-04-29 - Kvartalsrapport 2014-Q1
2014-03-21 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2014-03-20 - Bokslutskommuniké 2013
2013-11-15 - Kvartalsrapport 2013-Q3
2013-08-29 - Kvartalsrapport 2013-Q2
2013-05-15 - Kvartalsrapport 2013-Q1
2013-04-30 - Årsstämma
2013-04-30 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2013-03-14 - Bokslutskommuniké 2012
2012-11-29 - Kapitalmarknadsdag 2012
2012-04-26 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2012-04-25 - Årsstämma
2011-11-17 - Kvartalsrapport 2011-Q3
2011-10-25 - Kapitalmarknadsdag 2011
2011-08-18 - Kvartalsrapport 2011-Q2
2011-05-12 - Kvartalsrapport 2011-Q1
2011-04-29 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2011-04-28 - Årsstämma

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Zealand Pharma är verksamt inom bioteknik. Särskilt fokus återfinns inom utvecklingen av läkemedel för behandling av diabetes och diverse tarmsjukdomar. Bolaget innehar en varierad produktportfölj med separata varumärken som säljs på global nivå. Störst verksamhet finns inom den nordiska marknaden. Zealand Pharma grundades 1997 och har sitt huvudkontor i Söborg, Danmark.
2021-02-04 22:05:00

Company announcement – No. 5 / 2021


Zealand Pharma to Host R&D Day on March 5, 2021

  • Zealand Pharma’s virtual Research & Development Day on March 5, 2021 will highlight progress across R&D pipeline and five-year strategy.

Copenhagen, DK and Boston, MA, U.S. February 4, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that it will host its virtual R&D Day for analysts and investors with a live Q&A session at 4:00 p.m. CET (10:00 a.m. ET) on Friday, March 5.

Zealand will discuss progress across its development pipeline and present the five-year R&D strategy during a prerecorded session that will become available to the public on March 4th, 24 hours before the live Q&A session on March 5th.

The pre-recorded session and live webcast of the Q&A session will be available on the "Events & Presentations" page in the Investor section of the Company’s website at https://www.zealandpharma.com/events-cal. A replay of the webcast will be archived on the Company's website following the presentation.

# # #

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.
Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA).

For further information, please contact:

Zealand Pharma Investor Relations
Maeve Conneighton
Argot Partners
investors@zealandpharma.com

Zealand Pharma Media Relations
David Rosen
Argot Partners
media@zealandpharma.com